Genomic testing of tumors and cancerous tissue is now a basic step in deciding on a course of treatment for many types of cancer. Foundation Medicine, founded in 2010, is a leading provider of such tests. In late 2017, the FDA cleared the company to market the most comprehensive test on the market, called FoundationOne CDx, which analyzes tissue samples for alterations across 324 genes known to drive cancer and measures “tumor mutational burden,” help oncologists steer patients to genetically matched drugs made by pharma partners, immunotherapies, or clinical trials. The company has partnered with some 50 biotech and pharma companies to date. In September, the company got Breakthrough Devices designation for a broad “liquid biopsy” tests that analyzes blood for 70 genes tied to cancer growth, allowing doctors to monitor treatment response without doing invasive tissue samples. In June 2018, Swiss drug maker Roche paid $2.4 billion to fully acquire Foundation, having already claimed a majority stake in 2015.